obesity drug news today october 2025 glp-1 A network meta-analysis backed weight-loss benefits with several receptor agonists, with less certainty for newer-generation agents. Read more at the link in bio Alarming rise in weight loss

Saxenda may affect the way some medicines work and some other medicines may affect the way Saxenda works

[DOI] [PubMed] [Google Scholar] 675.Gutzwiller J.P., Drewe J., Goke B., Schmidt H., Rohrer B., Lareida J

1995 Jul;109(1):239246

Why Some Women May Want to Consider LARC Given the potential for reduced efficacy of OCPs, women using GLP agonists may want to consider Long-Acting Reversible Contraceptive (LARC) methods, such as IUDs and the birth control implant

2 Monotherapy is no longer available in the USA since Jan 2023, and lixisenatide-glargine (iGlarLixi) has been approved for type 2 diabetes

Proceedings of the National Academy of Sciences